Efficacy of a Synthetic Pentasaccharide, a Pure Factor Xa Inhibitor, as an Antithrombotic Agent – A Pilot Study in the Setting of Coronary Angioplasty

Summary

Aim of the study. To assess the antithrombotic properties of SR90107/ORG31540, a sulfated pentasaccharide, which enhances specifically antithrombin III mediated inactivation of factor-Xa, in a clinical setting known to promote arterial thrombosis, i.e. coronary angioplasty.

Methods and results. Percutaneous transluminal coronary angioplasty (PTCA) was carried out with conventional balloons with a single 5 min intravenous infusion of 12 mg pentasaccharide, and 500 mg intravenous aspirin. Heparin was not allowed before, during PTCA, and within 24 h after PTCA. The primary end point was the rate of abrupt vessel closure during and within 24 h after the procedure. The sample size was set at 60 evaluable patients, in order to be able to conclude with a good level of confidence (>95%) that the abrupt vessel closure rate was less than 10%, if less than 3 abrupt vessel closures were observed. Seventy-one patients were included in the study, of whom 10 needed elective stenting, and were not considered as evaluable for efficacy. Two out of the 61 remaining evaluable patients experienced acute vessel closure during the study period [3.28%, 95% confidence interval (0.4%; 11.4%)]. No major bleeding occurred. The drug plasma concentrations reached 1.91 ± 0.39 mg/l, 10 min after pentasaccharide injection, and decreased on average to 1.18 ± 0.27 mg/l at 2 h, and to 0.36 ± 0.11 mg/l at 23 h after administration of pentasaccharide. Activated clotting time (ACT) and activated partial thromboplastin (aPTT) time remained within normal range. Thrombinantithrombin complex levels fell from 22 ± 17.1 to 4.5 ± 3.4 μg/ml, prothrombin fragment 1+2 levels decreased from 2.15 ± 1.01 to 1.73 ± 0.87, and activated factor VII levels decreased from 43.4 ± 16.8 mU/ml to 18.9 ± 7.3 mU/ml respectively from baseline to 2 h following injection of the tested drug.

Conclusions. Administration of pentasaccharide led to the inhibition of thrombin generation without modification of aPTT and ACT. The rate of abrupt vessel closure was within range of rates reported in historical series. Thus we conclude that the anti-thrombotic activity of pentasaccharide, as shown in this pilot trial in the setting of coronary angioplasty, deserves further investigation.

• References

• 1 Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-Activity Relationship in Heparin: A Synthetic Pentasaccharide with High Affinity for Antithrombin III and Eliciting High Anti-Factor Xa Activity. Biochem Biophys Res Commun 1983; 116: 492-9.
• 2 Petitou M, Lormeau JC, Choay J. Chemical synthesis of glycosaminogly-cans: new approaches to antithrombotic drugs. Nature 1991; 350 suppl 30-3.
• 3 Herbert JM, Petitou M, Lormeau JC, Cariou R, Necciari J, Magnani HN, Zandeberg P, van Amsterdam RGM, van Boeckel CAA, Meuleman DG. SR90107A/ORG31540, a Novel Anti-Factor Xa Antithrombotic Agent. Cardiovasc Drug Rev 1997; 15: 1-26.
• 4 Amar J, Caranobe C, Sié P, Boneu B. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbit. Br J Haematol 1990; 76: 94-100.
• 5 Vogel GMT, Van Amsterdam RGM, Kop WJ, Meuleman DG. Pentasaccharide and Orgaran^® arrest, whereas heparin delays thrombus formation in a rat arterio-venous shunt. Thromb Haemost 1993; 69: 29-34.
• 6 Cadroy Y, Hanson SR, Harker LA. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non human primates. Thromb Haemost 1993; 70: 631-5.
• 7 Herbert JM, Herault JP, Bernat A, Van Amsterdam RG, Vogel GM, Lormeau JC, Petitou M, Meuleman DG. Biochemical and pharmacological properties of SANORG 32701. Comparison with the “synthetic pentasaccharide” (SR 90107/ORG 31540) and standard heparin. Circ Res 1996; 79: 590-600.
• 8 Pislaru SV, Pislaru C, Zhu X, Arnout J, Stassen T, Vanhove P, Herbert JM, Meuleman DG, van de Werf F. Comparison of a Synthetic Antithrombin III-binding Pentasaccharide and Standard Heparin as an Adjunct to Coronary Thrombolysis. Thromb Haemost 1998; 79: 1130-5.
• 9 Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J. Biochemical and Pharmacologic Rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86: 1-36.
• 10 Boneu B, Necciari J, Cariou R, Sié P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T, Magnani H. Pharmokinetics and tolerance of the natural pentasaccharide (SR 90107/ORG 31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74: 1468-73.
• 11 Ellis SG. Elective coronary angioplasty: technique and complication. In: Topol EJ. (ed.) Text Book of International Cardiology. WB Saunders Co, Philadelphia, PA; 1989: 186-206.
• 12 Bell MR, Reeder GS, Garratt KN, Berger PB, Bailey KR, Holmes Jr. DR. Predictors of major ischemic complications after coronary dissection following angioplasty. Am J Cardiol 1993; 71: 1402-7.
• 13 Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in Myocardial Infarction (TIMI) Trial – Phase I: Hemorrhagic Manifestations and Changes in Plasma Fibrinogen and the Fibrinolytic System in Patients Treated with Recombinant Tissue Plasminogen Activator and Streptokinase. J Am Coll Cardiol 1988; 11: 1-11.
• 14 Walenga JM, Fareed J. Preliminary biochemical and pharmacological studies on a chemically synthesized pentasaccharide. Semin Thromb Hemost 1985; 11: 89-99.
• 15 Rehr R, Disciascio G, Vetrovec G, Cowley M. Angiographic morphology of coronary artery stenosis in prolonged rest angina: evidence of intracoronary thrombosis. J Am Coll Cardiol 1989; 14: 1429-37.
• 16 Ambrose JA, Israel DH. Angiography in unstable angina. Am J Cardiol 1991; 68: 78B-84B.
• 17 De Feyter PJ, Ozaki Y, Baptista J, Escaned J, Di Mario C, de Jaegere PP, Serruys PW, Roelandt JR. Ischemia-related lesion characteristics in patients with stable or unstable angina. A study with intracoronary angioscopy and ultrasound. Circulation 1995; 92: 1408-13.
• 18 Alfonso F, Goicolea J, Hernandez R, Segovia J, Silva JC, Perez-Vizcayno MJ, Rollan MJ, Banuelos C, Macaya C. Findings of coronary angioscopy in angiographically normal coronary segments of patients with coronary artery disease. Am Heart J 1995; 130: 987-93.
• 19 White CJ, Ramee SR, Collins TJ, Escobar AE, Karsan A, Shaw D, Jain SP, Bass TA, Heuser RR, Teirstein PS, Bonan R, Walter PD, Smalling RW. Coronary thrombi increase PTCA risk. Angioscopy as a clinical tool. Circulation 1996; 93: 253-8.
• 20 Lincoff AM, Topol EJ. Abrupt vessel closure. In: Topol EJ. (ed.) Text Book of International Cardiology. WB Saunders Co, Philadelphia, PA; 1989: 207-30.
• 21 Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975; 69: 685-9.
• 22 Kuntz RE, Piana R, Pomerantz RM, Carrozza J, Fishman R, Mansour M, Safian RD, Baim DS. Changing incidence and management of abrupt closure following coronary intervention in the new device era. Cathet Cardiovasc Diagn 1992; 27: 183-90.
• 23 Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic, and therapeutic profile. J Am Coll Cardiol 1992; 19: 926-35.
• 24 De Feyter PJ, de Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994; 127: 643-51.
• 25 Sinclair IN, McCabe CH, Sipperly ME, Baim DS. Predictors, therapeutic options, and long-term outcome of abrupt reclosure. Am J Cardiol 1988; 61: 61G-66G.
• 26 Detre KM, Holmes DR, Holubkov R, Cowley MJ, Bourassa MG, Faxon DP, Dorros GR, Bentivoglio LG, Kent KM. Myler RK and coinvestigators of the National Heart, Lung, and Blood Institute’s Percutaneous Transluminal Coronary Angioplasty Registry. Incidences and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990; 82: 739-50.
• 27 Mabin TA, Holmes DR, Smith HC, Vlietstra RE, Bove AA, Reeder GS, Chesebro JH, Bresnahan JF, Orszulak TA. Intracoronary thrombus: Role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 5: 198-202.
• 28 Sherman CT, Litvack F, Grunfest W. et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986; 315: 913-9.
• 29 Piessens JH, Stammen F, Vrolix MC, Glazier JJ, Benit E, De Geest H, Willems JL. Effects of an ionic versus a nonionic low osmolar contrast agent on the thrombotic complications of coronary angioplasty. Cathet Cardiovasc Diagn 1993; 28: 99-105.
• 30 Bonan R, Roose PC, Suttorp MJ, van der Wieken LR, Bassand JPL, Legrand VM, Weiner BH, Adelman AG, Marquis JF, Barath P, Kuntz RE, Popma JJ. Cutting Balloon Global Randomized Trial: Restenosis and Revascularization Rate. Circulation 1997; 96: 1-324 (Abstract).
• 31 Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfield J, Bailey S, Ellis S, Rake R, Goldberg S. Stent Restenosis Study Invertigators. A randomized comparison of coronary-stent placement and balloon angioplasty in treatment of coronary artery disease (STRESS trial). N Engl J Med 1996; 331: 496-501.
• 32 Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon MB. Williams DO for the CAVEAT study group. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. N Engl Med J 1993; 329: 221-7.
• 33 Abdelmeguid AE, Whitlow PL, Sapp SK, Ellis SG, Topol EJ. Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. Circulation 1996; 93: 397-8.
• 34 Vogt A, Bonzel T, Harmjanz D, V. Leitner E-R, Pfafferott C, Engel H-J, Niederer W, Schuster P-R, Glunz HG, Neuhaus K-L. PTCA Registry of German Community Hospitals. Eur Heart J 1997; 18: 1110-4.
• 35 Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8.
• 36 D’angelo A, Gerosa S, D’angelo SV, Mailhac A, Colombo A, Agazzi A, Mazzola G, Chierchia S. Protein S and Protein C anticoagulant activity in acute and chronic cardiac ischemic syndromes. Relationship to inflammation, complement activation and in vivo thrombin activity. Thromb Res 1994; 75: 133-42.
• 37 Merlini PA, Bauer KA, Oltrona L. et al. Thrombin Generation and Activity during Thrombolysis and Concomitant Heparin Therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995; 25: 203-9.
• 38 Granger CB, Becker R, Tracy RP, Califf RM, Topol EJ, Pieper KS, Ross AM, Roth S, Lambrew C, Bovill EG. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1998; 31: 497-505.
• 39 Lormeau JC, Herault JP, Herbert JM. Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb Haemost 1996; 76: 5-8.